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ABSTRACT 
Meloxicam is a non steroid anti inflammatory drug that          
is classified as Biopharmaceutics Classification System (BCS)  
class II. Meloxicam is poorly soluble in water, therefore its 
solubility would be the rate limiting step for drug absorption. 
This study was conducted to improve meloxicam solubility using 
nanotechnology approach. Meloxicam nanocrystal was prepared 
using high pressure homogenization technique. Several 
stabilizers were investigated for suitable nanocrystal production. 
Formulation of suspension on the meloxicam nanocrystal was 
developed. Short physical stability was performed to assess the 
potential use of the stabilizer. Nanocrystal containing 10% 
meloxicam and 5% PVP K25 was formed faster with better 
physical stability compared to other stabilizers (xanthan gum, 
HPMC 2910 type 603 dan 645). Meloxicam nanocyrstal 
suspension containing meloxicam nanocrystal with stabilizer 5% 
or 10% of PVP K25 showed excellent particle size stability (with 
particle size 466.6nm and 486.9nm) and dissolution rate 
compared to reference product (without nanonization). Particle 
size and dissolution rate of meloxicam nanocrystal suspensions 
(containing 5% or 10% of PVP K25) were stable after storage for 
30 days at room temperature. Kinetic solubility of meloxicam 
nanocrystal  was three times higher than that of meloxicam. 
According to XRD profile, there was no differences in crystallinity 
between meloxicam and meloxicam nanocrystal.  
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INTRODUCTION 
Numbers of new drugs were developed 
and become challenge for pharmacy scientist to 
develop products with good bioavailability 
because of those poor solubility. Some of the 
traditional approaches could  overcome such 
solubility factors but resulting bioavailability 
problems. In this respect, nanoparticle 
technology could become promising solution. 
The major advantages of this technology are its 
general applicability to most drugs and its 
simplicity (Mauludin, et al., 2008).  
Meloxicam [4-hydroxy-2-methyl-N-(5-
methyl-2-thiazolyl)-2H -1,2-benzothiazine- 3-
carboxamide -1,1-dioxide], a nonsteroidal anti-
inflammatory drug (NSAID), is an enolic 
oxicam derivative that included in BCS class II.  
Meloxicam has a low solubility in aqueous 
media and low dissolution rate, which are 
limiting step to its absorption (Ambrus, et al., 
2009). It has been used for rheumatoid arthritis, 
osteoarthritis treatment. The anti-inflamation 
mechanism is by inhibiting cyclooxygenase 
(most of cyclooxygenase 2) and then inhibiting 
prostaglandin formation.  
Several techniques have been reported to 
enhance the meloxicam dissolution, such as 
nanosizing by emulsion-diffusion method 
(Ambrus, et al., 2009), nanosizing using co-
grinding for nasal powder (Kürti, et al., 2011), 
hot-melted method with premiling meloxicam 
(Nassab, et al., 2006), meloxicam-cyclodextrin 
complex (Naidu, et al., 2006). All these  reports 
have been established to improve meloxicam 
solubility in solid dosage form where physical 
particle interaction leading to particle 
agglomeration is diminished. But, it is a 
challenge to develop meloxicam nanoparticle 
for suspension dosage form with maintaining 
particle size while enhancing dissolution rate.  
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Suspension is binary system consist of 
colloidal particles in a dispersion medium. 
These particles show Brownian motion and 
hence collide with each other frequently. The 
stability of colloids is thus determined by the 
interaction between the particles during such a 
collision. There are two basic interactions: one 
being attractive and the other repulsive. When 
attraction dominates, the particles will adhere 
with each other and finally the entire dispersion 
may coalesce. Van der Waals forces are the 
primary source of attraction between colloidal 
particles (Rowe, 2009). Smaller particles show 
more energic motion, and probability to 
coalesce is higher. Particles stability obtained by 
surrounding colloidal particles with electrical 
double layer (electric stabilization), polymer 
adsorbed on the particle surface (steric 
stabilization). This stabilizations are providing a 
long range repulsion between the particles 
(Rowe, 2009). Particle size stability in 
nanocyrstal formulation is major factor to 
maintain solubility and dissolution  enhance-
ment. Therefore, investigation on potential 
stabilizers was studied with focusing on the 
process efficiency and the particle size with 
narrow distribution size.  
Meloxicam nanocrystal was prepared 
using high pressure homogenization technique. 
Several stabilizers providing both steric and 
electric stabilization on the surface of 
nanocrystal were evaluated for suitable 
meloxicam nanocrystal production. Meloxicam 
nanocrystal would be formulated to oral 
suspension dosage form in order to improve its 
dissolution rate, and expected to achieve fast 
onset of the peak plasma concentration.  
 
MATERIAL AND METHODS 
Meloxicam was obtained from 
Changzhou Xinhua, China. PVP K25 from 
Danochemo, hydroxypropyl methylcellulose 
(HPMC 2910) type 603 and type 645 were from 
Shin Etsu, Japan, polysorbate 80 was from 
Shino Japan Chemical, Japan.  Sodium lauryl 
sulfate (SLS) was from Cognis Indonesia. 
Xanthan gum was from Danisco, France. 
Sorbitol Sol 70% was from Roquette, France. 
Ethyl paraben was from Iporg. Saccharin was 
from Keifeng Xinhua Fine Chem, China.  
Sucralose was from Guangzhou, China. Citric 
acid was from Tate and Lyle, Australia. And 
poloxamer 188 was from BASF. 
 
Preparation of meloxicam nanocrystal 
Meloxicam and the stabilizer were first 
dispersed in an aqueous media in the volume 
scale of 500mL using Turbomixer (Euro ST PB 
IKA® Werke) and Ultra Turax (T25 IKA® 
Werke) and the suspension was milled with 
high pressure homogenizer (Panda Plus 2000, 
GEA Niro Soavy, Italy). Fine suspension then 
processed to premilling step at 200bar and 
500bar (two cycle each), continued with main 
milling step at 1000bar for 20cycle.  Samples 
were taken at cycle number of 5, 10, 15 and 20. 
Nanocrystal characterization include particle 
size, particle distribution and zeta potential.  
 
Meloxicam nanocrystal development 
Preliminary experiment  
In order to select the appropriate 
stabilizer, preliminary experiment using 
polysorbate 80 (1%), sodium lauryl sulfate 
(0.25%), xanthan gum (0.20%), PVP K25 (5%), 
HPMC 2910 type 603 and type 645 (5%) were 
performed. A solution of stabilizer in aqueous 
media (500mL) was mixed with meloxicam 
using Turbomixer and Ultraturax UT 25 for 
3min. Prospective stabilizer showed good 
dispersion stability and sedimentation. 
 
Study of polymer stabilizer to meloxicam 
nanocrystal characteristics 
Meloxicam nanocrystal  (containing 
meloxicam 10% in aqueous media) was develop 
using xanthan gum (0,20%), PVP K25 (5%), 
HPMC 2910 type 603 and type 645 (5%).  
Characterization of particle size were observed 
after main milling step at  cycle number 0, 5, 
10, 15 and 20. Prospective stabilizer  with good 
particle size stability and most efficient process  
resulting nanoparticle was choosed.  
 
Study of polymer concentration and addition 
of surfactant to meloxicam nanocrystal 
characteristics 
The choosen stabilizer was Meloxicam 
nanocrystal  (containing meloxicam 10% in 
aqueous media) was develop using xanthan 
gum (0,2%), PVP K25 (5%), HPMC 2910   
type 603 and type 645 (5%).  Characterization 
of particle size were observed after main  
milling step at cycle number 0, 5, 10, 15 and 20. 
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Prospective stabilizer  with good particle size 
stability and most efficient process  resulting 
nanoparticle was choosed.  
 
Characterization of nanocrystal 
Particle  size  and  zeta potential 
determination 
The particle sizes of the nanocyrstal were 
determined by photon correlation spectros-
copy, using a Particle Size Analyzer Delsa Nano 
C (Beckman Coulter). Results of this technique 
were performe as mean particle diameter and 
the range of the particle-size distribution 
(polydispersity index, PI). Zeta potentials were 
determined using the same instrument 
Hemholtz-Smoluchowski equation. 
 
Kinetic solubility of meloxicam 
Solubility studies were performed with 
roller mixer. Vials contained meloxicam 0.1% 
in aqueous media were sealed and shaken                
at 45rpm for 3days in room temperature 
condition. After 3days, suspensions were 
filtered twice through PALL® 0.2μm                 
filters (Pall Europe Limited, England, 0.293m). 
An filtrat from each vial was withdrawn  
assayed by high performance liquid 
chromatography to evaluate the amount of 
drug dissolved.  
 
Morphology of nanocrystal 
Morphology of nanocrystals determina-
tion were conducted using light microscopy 
and scanning electron microscope. Light 
microscopy was performed using Nikon 
Polarizing Microscope (Eclipse E501 Pol) with 
400x magnification.  
The surface morphology of the raw drug 
and nanocrystal were visualized by scanning 
electron microscopy (SEM). Samples were  
fixed onto a metallic holder and coated          
with gold to have a perfect image. Scanning 
electron microscope was used with an 
acceleration voltage of 10kV and a secondary 
detector. 
 
Determination of drug content  
Meloxicam content in nanocrystal and 
suspension were determined using high               
performance liquid chromatography (with 
isocratic elution system) using ultraviolet 
detector at 360nm and C18 column (United 
States, 2011).  
Crystalinity evaluation 
Crystalinity evaluation of meloxicam 
nanocrystal was evaluated using X-ray powder 
diffraction  (XRD) and differential scanning 
calorimetry (DSC). The crystalinity state of 
meloxicam in raw material and meloxicam 
nanocrystal was evaluated by X-ray diffraction 
(PW17170 BASED, Philips) using Cu anode 
tube and  the pattern was collected with a            
tube voltage of 40kV and a tube current of 
30mA.  
Endotermic or Exotermic profile of raw 
material and meloxicam nanocrystal was 
determined by Thermal Analysis (Shimadzu, 
60-series). Sample analyzed with heating speed 
10ºC/minute until 300ºC.   
 
Meloxicam nanocrystal suspension 
formulation 
Meloxicam nanocrystals using the most 
prospective stabilizer were formulated to oral 
suspension with concentration of 7.5mg 
meloxicam in 5mL suspension. Suspension 
base contained ethyl paraben, saccharin, 
xanthan gum, sorbitol sol and citric acid. 
Meloxicam nanocrystal suspension were store 
until 30 days at room temperature (30°C RH 
75%) and particle size and dissolution profile 
were observed. 
 
Determination of in vitro dissolution  
Samples contained 7.5mg of meloxicam 
were put in to dissolution flask (900mL of 
phosphate buffer solution (pH 7.4±0.1) at 
37±0.5°C) and then using paddle method with 
rotation speed of the paddles was 25rpm. At 
predetermined time intervals (after 5, 10, 15, 
30, and 45min), 7mL samples were withdrawn 
and the amount of dissolved drug was 
determined using ultraviolet  spectrophoto-
metry method at wavelength 360nm 
(Rachmawati, et al., 2009).  
 
RESULT AND DISCUSSION 
Preliminary stabilizer screening 
The influence of different stabilizer              
on meloxicam dispersion was investigated  
using Turbomixer and Ultra Turax. Prospective 
stabilizers are the one that have a wetting 
property for meloxicam (so meloxicam shall 
easily dispersed in to aqueous media) and have 
a stabilizing properties for meloxicam dispersion 
to   stay   homogenously   for   a  certain   time. 
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According to the results, polysorbate 80 and 
SLS showed very good wetting properties but 
very poor sedimentation    stability   (tends  to  
form cake).  
The polymeric stabilizers (xanthan gum, 
PVP K25, HPMC 2910 type 603 and type 645) 
show good stabilizer properties for meloxicam 
with there good wetting properties and 
sedimentation stability after 1day. Furthermore, 
four stabilizers were chosen for meloxicam 
nanocrystal preparation using high pressure 
homogenizer. 
 
Effect of polymer stabilizer to 
meloxicam nanocrystal characteristics 
Table I presents particle size reduction 
profile during the process and performace 
stabilizer to reduce the size of the particles. 
Mean diameter of meloxicam using four 
stabilizer relatively almost the same, with size 
range from 175nm until 205nm. Formula 
meloxicam nanocrystal using PVP K25 showed 
fastest particle size reduction ability compare to 
other stabilizer with good particle size 
distribution (PI : -0.390-0.077 %). According 
to nanocurcumin study (Rachmawati, et  al., 
2009), the higher the molecular weight                    
of   polymers   (in  this  case  is   Xanthan  gum,  
HPMCs), the slower was the decrease in 
particle size with increasing number of cycles. 
For that reason, PVP with lower molecular 
weight (Rowe, 2009) shows faster size reduction.  
Formula meloxicam nanocrystal using 
PVP K25 showed good stability after five days 
storage in room temperature.  According to Shi 
(2002), bulky and complex moleculs give good 
physical stability properties. PVP K25 have 
long and branches molecul structure, it shows 
good steric stabilizing properties. For the 
further meloxicam nanocrystal formulation, 
PVP K25 5% was chosen. 
 
Study of polymer concentration and 
addition of surfactant to meloxicam 
nanocrystal characteristics 
The average particle size of the resulting 
nanocrystal stabilized with PVP K25 5% was 
523.732.61nm, and that of the 
nanosuspension stabilized with PVP 10% was 
478.9517.47nm. When surfactants were used 
to formulate a nanocrystal, bigger particles were 
observed. Poloxamer 188 (formula PVP 5%-
Polx 1%) and polysorbate 80 (formula PVP 
5%-Polys 1%) addition to PVP K25 system 
disturb the stabilizers ability to form small 
particles (Table II). 
Table I. Meloxicam nanocrystal characteristic of several polymer stabilizer 
 
Stabilizer 
Parameters Xanthan gum 
0,25% 
PVP K25 5% 
HPMC 2910 
type 603 5% 
HPMC 2910 
type 645 5% 
Particle size     
Mean±SD (nm) 204.90±30.18 196.60±12.03 184.90±24.63 175.37±34.96 
Polydispersity Index     
Mean±SD (%) -0.500±-0.038 -0.390±-0.077 -0.368±-0.034 -0.369±-0.038 
Zeta potensial  (mV) -14.49 -10.99 -0.43 -0.48 
 




PVP K25 5% PVP K25 10% PVP 5%-Polys 1% PVP-Polx 1% 
Particle size     
Mean±SD (nm) 523.7±32,61 478.95±17.47 835.60±183.99 906.60±93.62 
Polydispersity Index     
Mean±SD (%) -0.452±-0.028 -0.681±-0.002 -1.873±-1.338 -2.292±-2.617 
Zeta potensial  (mV) -3.98 -1.27 -2.64 -1.53 
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Meloxicam nanocrystal using PVP             
K25 5% and 10% showed good particle size 
stability after 14 days, with average particle           
size  was 547.0527.08nm  and 497.750.35nm. 
Formula PVP K25 5%-Polx 1% and PVP K25 
5%-Polys 1%   showed   slight  increase  in  
particle   size. According to Ostwald Ripening 
theory, small particles have a large free energy 
and the thermodynamic unstable. To decrease 
their free energy, nanocrystals tend to reduce 
interaction with water via flocculation, 
aggregation or crystal growth (Verma, et al., 
2004).  According to the result, PVP K25 have 
a good stabilizing properties to prevent 
aggregation through steric stabilization 
mechanism. PVP K25 formed adsorbed layer 
on dispersed particles and minimizing 
interaction between nanoparticles (Shi, 2002). 
                                                                                                                                                                
Meloxicam nanocrystal suspension 
formulation 
Meloxicam nanocrystal that has been 
developed is applied on the basis of the 
suspension to get meloxicam nanocrystal 
suspensions Me Susp-1 (containing PVP K25 
5%), Me Susp-2 (containing PVP K25 10%), 
Me Susp-3 (containing PVP K25 5%-Polys 
1%), Me Susp-4 (containing PVP K25 5%-Polx 
1%). Observations were conducted on the 
particle size and dissolution rate. 
 
Particle size analysis 
Meloxicam particle size evaluation in 
suspension (Table III). The particle size in the 
suspension were smaller than the nanocrystal 
because of some small particles dissolve              
in    media   base   suspension (Khanam,  2007).  
 
Figure 1.   Initial dissolution profiles of meloxicam nanocrystal suspension 
 
Table III.  Particle size analysis of Meloxicam nanocrystal suspensions at initial and after 30 




Me Susp-1 Me Susp-2 Me Susp-3 Me Susp-4 
Initial         
Particle size     
Mean ±SD (nm) 278.05±5.16 297.60±10.18 626±23.05 347.55±38.25 
Polydispersity Index     
Mean±SD (%) 0.936±0.057 1.037±0.008 1.996±0.001 1.115±0.055 
After 30 days     
Particle size     
Mean ±SD (nm) 278.05±5.16 297.60±10.18 626±23.05 347.55±38.25 
Polydispersity Index     
Mean ±SD (%) 0.936±0.057 1.037±0.008 1.996±0.001 1.115±0.055 
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The average particle size of the resulting 
nanocrystal suspension stabilized with PVP 
K25 5% was 278.055.16nm, and that of the 
nanosuspension stabilized with PVP 10% was 
297.6010.18nm. Average particle size of the 
resulting nanocrystal suspension stabilized with 
PVP K25 5% and Polysorbate 80 1% was 
62623.05nm, and that of the nanosuspension 
stabilized with PVP K25 5% and Poloxamer 
188 1%  was 347.5538.25nm. In this study, 
meloxicam nanocrystal suspension using            
PVP K25 5% and 10% showed excellent 
particle size stability after 30 days storage               
at room temperature with average particle        
size  was 380.4014.57nm and 398.151.63nm. 
Xanthan gum participate in the prevention of 
nanocrystal agglomeration beside of stabiliza-
tion by PVP K25. According to research of 
Iron nanoparticles (Comba and Sethi, 2009), 
xanthan gum protected the particles and gives 
the distance between the particles, thereby 
reducing the attractive forces between particles.  
 
In vitro dissolution profile determination 
Figure 1 presents meloxicam nanocrystal 
dissolution profiles compared to meloxicam 
suspension (without nanonization). The rate of 
 
 
Figure 2. Scanning Electron Microscopy image of non nanosozing meloxicam (A1, A2) and 





Figure 3. XRD profiles of raw meloxicam, and 
meloxicam nanocrystal  
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dissolution of raw meloxicam, with particles in 
the micrometer size range, was very low: only 
50% of the drug was dissolved in the                  
first 10min; formulation of Me Susp-1 and Me 
Susp-2 samples of meloxicam doubled the 
dissolution rate (reaching 109% and 105% after 
10min). From the experimental results, particle 
size reduction can increase dissolution rate.  
According to the Noyes-Whitney quation 
(Suman, 2009), high solute concentration 
versus time (dX/dt) is proportional to the 
surface area (A) and  the surface area (A) is 
inversely proportional to particle size (D) by 
the formula A=6/(Dxρ), with D as the 
diameter of the particle. According to Prandtl 
equation, the diffusion layer thickness (h) of 
very small particles decreases while h is 
inversely proportional to the rate of dissolution 
so that the dissolution rate increases (Mauludin, 
2008). Stability dissolution rate remained stable 
as xanthan gum can slow the increase in 
particle size. The rate of dissolution of Me 
Susp-1 and Me Susp-2  was still high, with 
dissolved concentration within 96.2% and 
94.01% after first 10min.  
 
Kinetic solubility analysis 
Kinetic solubility meloxicam nanocrystal 
increased to 3-fold (28.41%) when compared to 
with the raw material (9.04%). According to 
Ostwald-Freundlich equation and the Kelvin-
Gibbs, nanosuspensi solubility will increase 
when compared to microsuspension (Müller, 
2004; Buckton, 1992). 
 
Morphology of meloxicam nanocrystal 
Morphology of meloxicam nanocrystal 
was obsereved using an optical microscope 
with a magnification of 400x and  Scanning 
Electron Microscopy (SEM) with a 
magnification of 500x and 20000x (Figure 2). 
Results are shown in the optical microscope 
and SEM ranges similar to those analysed using 
Particle Size Analyzer. 
 
Crystallinity evaluation 
Crystallinity evaluation of raw material 
and meloxicam nanocrystal were presented at 
figure 3 using X-ray diffraction method (XRD). 
XRD profile between raw material and 
meloxicam nanocrystal were similar. This is 
show that nanosizing process using high 
pressure homogenizer did not influence 
meloxicam crystallinity behavior. 
There was slight shifting of endotermic 
peak (with DSC analysis) from meloxicam 
nanocrystal compared to raw material melting 
point peak. This is presumably due to the 
influence of PVP K25 which has a low melting 
point.  These examinations show that the 
increase of dissolution rate is caused by particle 




High pressure homogenization methods 
was succeded to produce meloxicam 
nanocrystals with particle size  in range of 523.7 
until 478.95nm.  PVP K25 5% and 10% was 
the most suitable stabilizer for nanocrystal. 
Meloxicam nanocrystal shown better solubility 
than raw micro-sized particles. Meloxicam 
nanocrystal suspension shown higher 
dissolution profile compare to meloxicam 
suspension without nanonization.   
Pharmacokinetic study suggest to 
conduct in vitro and in vivo correlation of 
meloxicam nanocrystal suspension. 
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